Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

UNCOVERED: Merck reveals mixed data from keytruda lynparza regime in ovarian cancer - The Untold Story

On Monday, Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial.

The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza (olaparib), with or without bevacizumab, as a first-line treatment for BRCA non-mutated advanced epithelial ovarian cancer met its primary endpoint of progression-free survival.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.